{"entity":{"id":"nct06096844","kind":"trial","name":"Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial","aka":[],"tldr":"A phase 3 trial of carboplatin, nab-paclitaxel, paclitaxel / nab-paclitaxel, pembrolizumab and other drugs in lung cancer, run by National Cancer Institute (NCI), now recruiting.","summary":"Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial is a phase 3, randomised interventional study registered as NCT06096844 by National Cancer Institute (NCI), with a registry enrolment figure of 304 participants, started 2024-07-19 and due to reach its primary completion in 2039-04-01. Interventions recorded: Carboplatin; Computed Tomography; Magnetic Resonance Imaging; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Pemetrexed; Positron Emission Tomography; Questionnaire Administration. Conditions listed: Advanced Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8. Primary outcome: Overall survival (OS). Lung eligibility wording from the registry: \"* Patient must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC) with PD-L1 Tumor Proportion Score (TPS) range of 1-49%\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06096844","url":"https://clinicaltrials.gov/study/NCT06096844"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["carboplatin","nab-paclitaxel","paclitaxel","pembrolizumab","pemetrexed"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06096844","phase":"3","setting":"A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult With Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study","sponsor":"National Cancer Institute (NCI)","enrolled":304,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06096844/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}